Health TrialsbyHealthPanel

Coenzyme Q10 in Pediatric Community-Acquired Pneumonia

ConditionCommunity Acquired Pneumonia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2-18
SponsorTanta University

About this trial

The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia

Disqualifiers

Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.

Trial design

Design model

Parallel

Treatments tested in this trial

  • oral coenzymeQ10

    Drug

    60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: 60 children with community acquired pneumonia will receive oral coenzymeQ10Experimental treatment 1 intervention
Group B: 60 children with community acquired pneumonia with the standard pneumonia treatment.No intervention 0 interventions

Trial outcomes

Primary outcomes

1

Normalization of respiratory rate

Time frame
3 days
2

Normalization of temperature

Time frame
3 days
3

Normalization of oxygen saturation

Time frame
3 days
4

Normalization of Feeding Behavior Assessed by Oral Intake Tolerance

Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.

Time frame
3 days

Secondary outcomes

1

Length of hospital stay

Time frame
10-21 days
2

Number of Participants Requiring Surgical Intervention

This outcome measures whether a participant undergoes any surgical intervention related to the study condition during the follow-up period. Surgical intervention is defined as any operative procedure performed under general or regional anesthesia, as documented in the medical record. The outcome will be recorded as a binary variable (Yes/No) for each participant and summarized as the number and proportion of participants requiring surgical intervention.

Time frame
21-30 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tanta University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: